2024 Publications

  1. Halloran PF, Madill-Thomsen KS, Aliabadi-Zuckermann A, Cadeiras M, Crespo-Leiro M, DePasquale E, et al. Redefining the molecular rejection states in 3230 heart transplant biopsies: relationships to parenchymal injury and graft survival. Am J Transplant. 2024;24(8):1414-1426.
  2. Sikosana MLN, Reeve J, K.S. M-T, Halloran PF, and the INTERCOMEX Investigators. Using regression equations to enhance interpretation of histology lesions of kidney transplant rejection. Transplantation 2024;108(2):445-454.
  3. Halloran PF, Reeve J, Mackova M, Madill-Thomsen KS, Demko Z, Olymbios M, et al. Comparing Plasma Donor–derived Cell-free DNA to Gene Expression in Endomyocardial Biopsies in the Trifecta-Heart Study. Transplantation. 2024;108(9):1931-1942.
  4. Schmidt-Ott KM, Hinze C, Lovric S, Halloran PF, Barasch J. Epithelial cell states associated with kidney and allograft injury. Nat Rev Nephrol. 2024;20(7):447-459.
  5. Zajacova A, Mackova M, Halloran K, Gauthier P, Balko J, Guney M, et al. Treatment Responses in Histologic Versus Molecular Diagnoses of Lung Rejection. Transpl Int. 2024;37:12847.
  6. Viklicky O, Hruba P, Novotny M, Kment M, Halloran PF, Bohmig G. Targeting CD38 in subclinical antibody-mediated rejection in HLA-incompatible kidney transplantation – A case report. Transplantation Direct. 2024;10(8):p e1685.
  7. Mayer KA, Schrezenmeier E, Diebold M, Halloran PF, Schatzl M, Schranz S, et al. A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. N Engl J Med. 2024;391(2):122-32.
  8. Madill-Thomsen KS, Halloran PF. Precision diagnostics in transplanted organs using microarray-assessed gene expression: concepts and technical methods of the Molecular Microscope(R) Diagnostic System (MMDx). Clin Sci (Lond). 2024;138(11):663-85.
  9. Madill-Thomsen KS, Gauthier PT, Abouljoud M, Bhati C, Bruno D, Ciszek M, et al. Defining an NK cell-rich rejection-like phenotype in liver transplant biopsies from the INTERLIVER study. Transplantation. 2024;In press.
  10. Halloran PF, Madill-Thomsen KS, Reeve J. The Molecular Phenotype of Kidney Transplants: Insights From the MMDx Project. Transplantation. 2024;108(1):45-71.
  11. Halloran PF, Madill-Thomsen KS, Bohmig G, Bromberg J, Budde K, Barner M, et al. Subthreshold rejection activity in many kidney transplants currently classified as having no rejection. Am J Transplant. 2024;In press.(https://doi.org/10.1016/j.ajt.2024.07.034).
  12. Halloran PF, Madill-Thomsen K, Mackova M, Aliabadi-Zuckermann AZ, Cadeiras M, Crespo-Leiro MG, et al. Molecular states associated with dysfunction and graft loss in heart transplants. J Heart Lung Transplant. 2024;43(3):508-18.
  13. Gauthier PT, Madill-Thomsen KS, Demko Z, Prewett A, Gauthier P, Halloran PF, et al. Distinct Molecular Processes Mediate Donor-derived Cell-free DNA Release From Kidney Transplants in Different Disease States. Transplantation. 2024;108(4):898-910.
  14. Diebold M, Vietzen H, Heinzel A, Haindl S, Herz CT, Mayer K, et al. Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammation. Am J Transplant. 2024;24(5):743-54.
  15. Diebold M, Farkash EA, Barnes J, Regele H, Kozakowski N, Schatzl M, et al. Natural Killer Cell Presence in Antibody-Mediated Rejection. Transpl Int. 2024;37:13209.